Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION D	ISCLOSURE
STATEMENT BY	APPLICANT
(Not for submission un	der 37 CFR 1.99)

Application Number		10803663		
Filing Date		2004-03-18		
First Named Inventor	DeWitt, Jr. et al.			
Art Unit		2122		
Examiner Name	Dam, Tuan Quang			
Attorney Docket Numb	er	AUS920030548US1		

				1	,					
					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	mber Kind Code1 Issue Date Name of Patentee or Applicat			Releva	Columns,Lines when ant Passages or Rele s Appear			
	1	6944720	B2	2005-0	19-13	Sperber et al.				
	2	7035996	B2	2006-0	H-25	Woodall et al.				
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	nation pl	lease click the	Add button.		Add	
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Pat of cited Doci	entee or Applicant urnent	Releva	,Columns,Lines whei ant Passages or Rele s Appear	
lf you wis	Ċ	dd additional U.S. Publ	ished Ap			n information		d button	Add Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	Pages, Columns, Line where Relevant Passages or Relevar Figures Appear	
	1									
If you wis	h to a	dd additional Foreign F	atent Do	cument	citation	information p	lease click the Add	button	Add	
,						RATURE DO			Remove	

		Application Number		10803663	
	INFORMATION DIGGI COURT	Filing Date		2004-03-18	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	st Named Inventor DeWitt, Jr. et al.		
(Not for submission under 37 CFR 1.99)	Art Unit		2122		
	(,	Examiner Name Dam		m, Tuan Quang	
		Attorney Docket Numb	er	AUS920030548US1	

Examine Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţs
	1	TANENBAUM, "Structured Computer Organization", Prentice Hall, 1984, pp. 10-12.	

If you wish to add additional non-patent literature document citation information please click the Add button Add

FYAMINER SIGNATURE

Examiner Signature | Date Considered | Date Considered |

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

18e Kind Code of USPTO Petert Documents at time USPTO_GOLV or MPEP 961.94. 2 Enter office that issued the document, by the love-later code (WIPO Standard S13.) 2 "For Laptanese patient counters, the arcidation or the year of the eight of the Emperor many precised the sent annumber of the patient come of the patient or laptanese patient counters, the arcidation of the part of the patient or laptanese patient code (WIPO Standard S13.) 2 "For Laptanese patient code (WIPO Standard S17.16 if possible. 2 Applicant is to place a check mark here if English languages the relation is altituded."

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10803663	
Filing Date		2004-03-18	
First Named Inventor	DeWitt, Jr. et al.		
Art Unit		2122	
Examiner Name	Dam, Tuan Quang		
Attorney Docket Number		AUS920030548US1	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and	1.98 to make the appropriate selection(s):
----------------------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(a)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of Information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) The 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) the statement of the control of

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Gerald H. Glanzman/	Date (YYYY-MM-DD)	2006-08-03				
Name/Print	Geraid H. Glanzman	Registration Number	25035				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GAD 47 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient of the patient application or patient. If you do not furnish the requested related to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may related that the patient process and/or examine your submission.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a pleath pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.